Skip to Content
Merck
CN

SML2159

Minodronic acid monohydrate

≥98% (HPLC)

Synonym(s):

[1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene]bisphosphonic acid monohydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C9H12N2O7P2 · H2O
CAS Number:
155648-60-5
Molecular Weight:
340.16
UNSPSC Code:
12352106
NACRES:
NA.77
MDL number:
MFCD20037380

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Minodronic acid monohydrate, ≥98% (HPLC)

InChI

1S/C9H12N2O7P2.H2O/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8;/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18);1H2

SMILES string

OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2N1C=CC=C2.O

InChI key

GPAPAOGRNKUFGH-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

0.1 M NaOH: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

Related Categories

Biochem/physiol Actions

Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase
Minodronate is a third-generation bisphosphonate used clinically alone or in combination to treat osteoporosis. It is an inhibitor of farnesyl diphosphate synthase that acts as a bone resorption inhibitor.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000041079
0000041078
0000028196

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tsuyoshi Ohishi et al.
Endocrine research, 42(3), 232-240 (2017-03-21)
Monthly regimen of minodronate for osteoporosis more than two years has not been reported yet. The aim of this study is to elucidate the effect of monthly minodronate (M-MIN) on bone mineral density (BMD) and serum pentosidine (Pen) during 27
Motoaki Yasukawa et al.
Anticancer research, 36(11), 5883-5886 (2016-10-30)
Non-small cell lung carcinoma (NSCLC) is one of the leading causes of cancer-related death worldwide. Recent studies showed that nitrogen-containing bisphosphonates (N-BPs) directly and indirectly prevent proliferation, induce apoptosis, and inhibit metastasis of various types of cancer cell. In order
Shinichi Nakatoh
Journal of bone and mineral metabolism, 36(2), 221-228 (2017-03-16)
This study reveals the changes in bone mineral density (BMD), the turnover rate, and the balance [multiple of median formation/multiple of median resorption (MoMf/MoMr)] affected by the selection of different bone resorption inhibitors after 24-month daily teriparatide (20 µg/day) administration.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service